KIR2DL4 and breast carcinoma: Finally, we probed the role of HLA-G/KIR2DL4 in the response of clinical breast cancer to trastuzumab using neoplastic specimens of trastuzumab-resistant and trastuzumab-sensitive patients (Table 2).